NetworkNewsBreaks

ThursdayMar 30, 2017 10:33 am

NetworkNewsBreaks – MySize (NASDAQ: MYSZ) Trades Higher on Commercial Phase of KatzID Development

MySize (NASDAQ: MYSZ) shares are up 19% this morning after the company said it has completed the beta-pilot testing phase and has initiated the commercial phase of KatzID, a courier measurement application developed by MySize. KatzID will enable employees of Katz Corporation to easily and quickly measure the size of a parcel and calculate its exact shipping cost. The application also delivers barcode scanning, package pictures, location and more, which connect to Katz' ERP system to better manage their delivery processes. "Today marks a major milestone in the development of a very important product that is going to significantly improve…

Continue Reading

WednesdayMar 29, 2017 1:15 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 29, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: DCSA 29.86% – News: Secures first coffee shop site in Manchester, UK SGLB 16.95% – News: Enters long term commercial agreement with Additive Industries B.V. VTGN 12.83% – News: Receives notice of intention to grant AV-101 patent from European Patent Office WKHS 12.67% – News: Attending the U.S. Department of Transportation 50th Anniversary ceremony March 29 RBNW 10.00% – News: Completes capital restructuring, secures new funding GRMX 9.14% – News: Launches proprietary fabrics in…

Continue Reading

WednesdayMar 29, 2017 1:14 pm

NetworkNewsBreaks – Recro Pharma, Inc. (NASDAQ: REPH) Receives ‘Buy’ Rating at Aegis Capital, PT Adjusted to $11

Aegis Capital has issued a ‘Buy’ rating and an adjusted price target of $11 on shares of Recro Pharma’s (NASDAQ: REPH) stock. Aegis lowered the price target to $11 from $25 as a result of the recent dilutive capital raise. Recro recently reported financial results for the year ended December 31, 2016. For the fourth quarter of 2016, the company reported revenue of $17.4 million, surpassing street consensus estimates of $13.8 million. Additionally, over the past year, the company has reported positive data for IV Meloxicam from two pivotal phase 3 trials, which Aegis cited as a catalyst for the…

Continue Reading

WednesdayMar 29, 2017 1:11 pm

NetworkNewsBreaks – Novocure (NASDAQ: NVCR) Receives ‘Buy’ Rating, $14 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and $14 price target on shares of Novocure’s (NASDAQ: NVCR) stock. The report cites the company’s 151% growth in net revenues from 2015 to 2016 and attributes this growth primarily to Novovure’s Tumor Treating Fields (TTFields) technology. TTTFields have been approved for use in the U.S. and internationally for treating glioblastoma (GBM) patients. The company has big plans for 2017, including continuous market adoption in the U.S. and geographical expansion in Germany and Japan. For more information, visit www.novocure.com About Novocure Novocure is an oncology company developing a profoundly different cancer treatment centered…

Continue Reading

WednesdayMar 29, 2017 1:09 pm

NetworkNewsBreaks – Innocoll (NASDAQ: INNL) Receives FDA Meeting Minutes for XARACOLL® NDA; Shares Rally

Innocoll Holdings (NASDAQ: INNL) shares soared as much as 43% this morning – currently up 14% - after the company said it received formal Type A Meeting minutes from the United States Food and Drug Administration (FDA) relating to its New Drug Application (NDA) for XARACOLL. This clarifies the data that the company will need in order to address the questions raised in the Refusal to File (RTF) Letter the company received from the FDA in December 2016. During the Type A meeting, representatives of the FDA provided guidance which was confirmed in the formal FDA meeting minutes. The company…

Continue Reading

WednesdayMar 29, 2017 11:10 am

NetworkNewsBreaks – Players Network, Inc. (PNTV) Presenting at America First Investment Luncheon on March 31, 2017

Players Network’s (OTCQB: PNTV) CEO Mark Bradley and Director Brett H. Pojunis are set to present at the "America First Investment" financial luncheon hosted by ClubsCorp Business Network in Las Vegas on March 31, 2017, from 12:30-3:00 p.m. PDT. The diversified holding company was invited to present at the luncheon series that features select emerging companies who will present to attending investment bankers, institutional investors, and individual accredited investors. In addition to the presentation, both Bradley and Pojunis will be available for one-on-one meetings with investors. To register visit: https://goo.gl/gnkPRJ To view the full press release, visit: http://nnw.fm/Z3TrT About Players…

Continue Reading

TuesdayMar 28, 2017 1:59 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 28, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: VPRB 23.00% – News: Sets date for grand opening of The Vape and Smoke Store on April 20 VTSI 21.67% – News: Secures international contract; sets record number of Q1 orders MBII 11.49% – News: Advancing novel bacteria and related proteins identified by Evogene (NASDAQ: EVGN) into bioinsecticide pipeline IGXT 14.12% – News: Receives exclusive license for Tadalafil ED dosing patent RPMT 10.00% – News: Inks definitive agreement with Be Informed BV STRM 8.33%…

Continue Reading

TuesdayMar 28, 2017 10:58 am

NetworkNewsBreaks – Cempra, Inc. (NASDAQ: CEMP) Pulls Marketing Authorization Application for Solithromycin in Europe

Shares of Cempra (NASDAQ: CEMP) are down 5% mid-morning after the company said that it has withdrawn its marketing authorization application (MAA) seeking European Medicines Agency (EMA) approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired pneumonia in adults. The decision to withdraw was made based off of the Day 120 questions from the EMA, which caused the company to believe that additional data would be required. The company is now able to realign its strategy to provide additional data to both the EMA and U.S. Food and Drug Administration (FDA) to support potential approval.…

Continue Reading

TuesdayMar 28, 2017 10:45 am

NetworkNewsBreaks – Akers Biosciences, Inc. (NASDAQ: AKER) Receives Initial Order for Cholesterol Test from First Check; Shares Surge

Shares of Akers Biosciences (NASDAQ: AKER) climbed 71% on news of the company receiving an initial order for its rapid cholesterol self-test from First Check Diagnostics, LLC, the exclusive distributor for this product in the United States, for sale under its popular "First Check" brand. Akers’ Tri-Cholesterol "Check" test provides an estimate of a person's total cholesterol as well as his or her high density lipoprotein cholesterol levels, or 'good cholesterol'. This provides the user with an estimate of his or her low density lipoprotein levels, or 'bad cholesterol', making it an effective screening test for high cholesterol. "I am…

Continue Reading

TuesdayMar 28, 2017 10:41 am

NetworkNewsBreaks – RXi Pharmaceuticals Corp. (NASDAQ: RXII) Strengthens RXI-109 Intellectual Property with New Patent in Japan; Shares Rise

RXi Pharmaceuticals (NASDAQ: RXII) shares are up more than 38% this morning after the company said it has been granted a patent by the Japan Patent Office for the composition of matter of sd-rxRNAs targeting connective tissue growth factor for the treatment or prevention of fibrotic disorders. Fibrotic disorders covered include, but are not limited to, skin fibrosis and proliferative retinopathy. This patent includes RXI-109, the company’s lead clinical candidate, which is currently being evaluated in phase 2 clinical trials. The patent will expire in 2031. "The granting of this patent in Japan further strengthens RXi's intellectual property estate for…

Continue Reading